speaker-icon

Latest Posts

Partex-NV-announces-collaboration-with-Althea-DRF-Lifesciences

28

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More
Partex-Group-presents-results-from-a-pilot-project-with-AIO

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Partex-Sanofi-press-release-illustration

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi’s out-licensing portfolio.

Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion of an innovative approach which leverages Partex’s AI arm, Innoplexus, and its proprietary AI technology to identify new indications within Sanofi’s out-licensing portfolio. Through meticulous indication expansion, prioritization, and lab validation studies, the collaboration endeavours to uncover fresh prospects for Sanofi’s out-licensing portfolio.

As a crucial component of this collaboration, Innoplexus will embark on a journey to scan, analyse, and enrich multiple out-licensing asset candidates, spanning therapeutic areas. The overarching vision is to explore avenues for repurposing or repositioning these assets for out-licensing focusing on patients’ needs.

Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative milestone collaboration, stating, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery. By harnessing the power of AI, we aspire to unlock the hidden potential within Sanofi’s out-licensing portfolio and bring hope to patients suffering from unmet medical needs. This collaboration is a testament to our shared commitment to advancing healthcare through cutting-edge technology.”

The collaboration is already in motion, with the selection of the first three assets for AI predictions, set to be completed in 2024.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing anavex_partex_partnership_Innoplexus

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…